Dedicated to Discovery. Committed to Care.

1999 Annual Report

Treasurer's Report and Dana-Farber Governance

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

For the Fiscal Year Ended Sept. 30
(Dollars in thousands)

1999

1998


Revenues

 

 

Research

$103,974

$93,800

Patient Service, net

91,541

77,622

Unrestricted Jimmy Fund Contributions and Bequests

18,920

14,696

Other Operating

11,088

10,436

Total Revenues

225,523

196,554


Expenses

 

 

Direct Research

80,930

68,659

Direct Patient Care

71,410

58,653

Indirect

94,061

84,177

Total Operating Expenses

246,401

211,489


Deficit Before Investment Return

(20,878)

(14,935)

Realized Investment Return, net

29,590

24,425

Excess of Revenues Over Expenses

8,712

9,490

Net Unrealized Investment Gains (Losses)

17,155

(34,683)

Net Assets Released from Restrictions for Capital

434

2,743

Other Transfers

(1,500)

Increase (Decrease) in Temporarily Restricted Net Assets

19,345

(2,593)

(Decrease) Increase in Permanently Restricted Net Assets

(12,968)

16,334

Increase (Decrease) in Net Assets

32,678

(10,210)

Net Assets at Beginning of Year

362,462

372,672


Net Assets at End of Year

$395,140

$362,462

The preceding selected consolidated financial data as of September 30, 1999 and 1998 and for each of the years then ended, except for the Summary Statistical Data, have been derived from the consolidated financial statements of Dana-Farber Cancer Institute, Inc. and Dana-Farber, Inc., which have been audited by Ernst & Young, LLP, independent auditors.